Sein Métastatique SAFIR02 Breast Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer. Paris, Saint-Cloud MARIE PAULE SABLIN
Appareil Digestif REGIRI (PRODIGE 58) A randomised phase II trial assessing REGorafenib combined with IRInotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas Paris, Saint-Cloud
Appareil Digestif DS8201-A-U207 DESTINY CRC02 A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Participants With HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02) Saint-Cloud
Sein Métastatique MONDRIAN Chemotherapy Monitoring by Circulating Tumor DNA (ctDNA) in HER2 (Human Epidermal Growth Factor Receptor-2)- Metastatic Breast Cancer (MONDRIAN): a Phase 2 Study Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD, FRANCOIS-CLEMENT BIDARD
Appareil Digestif TEDOPaM Prodige 63 A randomized non-comparative phase II study of Maintenance therapy with OSE2101 plus FOLFIRI, or FOLFIRI after induction therapy with FOLFIRINOX in patients with locally advanced or metastatic Pancreatic ductal adenocarcinoma (TEDOPaM - D17-01 PRODIGE 63 Study). Saint-Cloud
Appareil Digestif ProActIF-01 ProActIF-01 Trial: Randomized phase II study of evaluation of an Individualized Program of nutrition and adapted physical Activity in Frail patients with advanced lung or digestive cancers Paris, Saint-Cloud
Appareil pulmonaire IONESCO (IFCT-1601) A Phase II Prospective Immune Neoadjuvant Therapy Study of Durvalumab (MEDI4736) in Early Stage Non-small Cell Lung Cancer. Saint-Cloud MARIE ANGE MASSIANI
Recherches "plusieurs pathologies" AcSé Pembrolizumab Secured Access to Pembrolizumab for Adult Patients With Selected Rare Cancer Types. Saint-Cloud CAROLE SOUSSAIN
Recherches "plusieurs pathologies" AcSé Vemurafenib Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations Saint-Cloud ETIENNE BRAIN
Recherches "plusieurs pathologies" SUMMIT- PUMA-NER-0502 An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification. Saint-Cloud FRANCOIS-CLEMENT BIDARD